Alpha Tau Medical Publishes Pooled Analysis Of Alpha DaRT Therapy In Journal *Cancers*; Data From 4 International Trials Show Nearly 100% Overall Response Rate And 89% Complete Response Rate In Treated Lesions
Portfolio Pulse from Benzinga Newsdesk
Alpha Tau Medical has published a pooled analysis of its Alpha DaRT therapy in the journal *Cancers*. The data from four international trials show a nearly 100% overall response rate and an 89% complete response rate in treated lesions. Additionally, there were no severe long-term toxicities, and the 2-year local recurrence-free survival rate was 77%.
June 25, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpha Tau Medical's Alpha DaRT therapy has shown impressive results in a pooled analysis published in the journal *Cancers*. The therapy achieved nearly 100% overall response rate and 89% complete response rate in treated lesions, with no severe long-term toxicities and a 2-year local recurrence-free survival rate of 77%.
The publication of these positive results in a reputable journal is likely to boost investor confidence in Alpha Tau Medical. The high response rates and lack of severe long-term toxicities are particularly encouraging, suggesting strong potential for the therapy's future success.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100